In a patient taking hydralazine 50 mg twice daily with a blood pressure of 178/82 mm Hg, should amlodipine (Norvasc) 5 mg be added daily?

Yes, adding amlodipine 5 mg daily is appropriate for this patient with uncontrolled hypertension on hydralazine monotherapy.

Your patient's blood pressure of 178/82 mmHg on hydralazine 50 mg twice daily represents inadequately controlled hypertension requiring treatment intensification. The 2017 ACC/AHA guidelines establish a target BP of <130/80 mmHg for most adults 1, and this patient's systolic BP of 178 mmHg is significantly above goal.

Why Amlodipine is the Right Choice

Adding amlodipine (a calcium channel blocker) to hydralazine is a rational and evidence-based combination. The 2018 Hypertension Canada guidelines recommend that when BP is not controlled with monotherapy, additional antihypertensive drugs should be added from first-line choices, including long-acting CCBs like amlodipine 2. The 2024 ESC guidelines similarly endorse dihydropyridine CCBs as first-line treatments with demonstrated effectiveness in reducing BP and cardiovascular events 3.

Dosing Considerations

Start with amlodipine 5 mg once daily as recommended by the FDA label 4. This is the standard initial antihypertensive dose for adults. The FDA label specifies that dosage adjustments should generally occur at 7-14 day intervals, though more rapid titration is acceptable if the patient is assessed frequently 4. If BP remains uncontrolled after 2 weeks, the dose can be increased to the maximum of 10 mg daily.

Expected Blood Pressure Response

Research demonstrates that amlodipine monotherapy reduces systolic BP by approximately 16-17.5 mmHg 5, 6. In your patient already on hydralazine, adding amlodipine should provide substantial additional BP reduction. Studies show amlodipine provides effective 24-hour BP control with once-daily dosing, maintaining the normal circadian pattern 7, 8.

Important Clinical Considerations

Why Not Just Increase Hydralazine?

Hydralazine is not an ideal first-line agent for chronic hypertension management. The ACC/AHA guidelines note that hydralazine has "unpredictability of response and prolonged duration of action" that make it undesirable as a first-line agent 1, 9, 10. It's primarily reserved for:

• Hypertensive emergencies (IV form)
• Heart failure patients (combined with nitrates) who cannot tolerate ACE inhibitors or ARBs 11, 2
• Patients with specific contraindications to other agents

Common Pitfalls to Avoid

1. Don't use PRN antihypertensives instead of optimizing scheduled therapy. Studies show that 40.8% of hospitalized patients receiving PRN hydralazine were not continued on their home medications, and 62.4% didn't have regimens intensified at discharge 12. This represents suboptimal management.

2. Monitor for peripheral edema. Amlodipine can cause dose-dependent ankle edema (occurs in 1.8-10.8% depending on dose) 4. This is usually mild but may require dose adjustment or discontinuation in some patients.

3. Watch for hypotension. While gradual-onset hypotension is unlikely with amlodipine due to its slow onset of action 4, monitor BP regularly, especially in elderly or frail patients.

Optimal Long-Term Strategy

Consider transitioning away from hydralazine entirely once BP is controlled. The 2025 AHA/ACC guidelines recommend first-line therapy with ACE inhibitors, ARBs, CCBs, or thiazide/thiazide-like diuretics 13. A more evidence-based regimen might be:

• Amlodipine + ACE inhibitor or ARB (preferred combination per guidelines 2, 3)
• Or amlodipine + thiazide-like diuretic (chlorthalidone or indapamide)

If the patient has heart failure with reduced ejection fraction (<40%), the hydralazine should be combined with isosorbide dinitrate rather than discontinued 11, 2, 14, but amlodipine can still be added for BP control if needed (though use caution as CCBs are not routine treatment for HFrEF 15, 11).

Monitoring Plan

• Reassess BP in 1-2 weeks after starting amlodipine
• Titrate to amlodipine 10 mg daily if BP remains >130/80 mmHg
• Consider adding a third agent (preferably ACE inhibitor/ARB or thiazide-like diuretic) if BP still uncontrolled on two drugs
• Evaluate for secondary causes of hypertension if resistant to 3-drug therapy 13